PortalPublikationenHBcrAg Levels Are Associated With Virological Response to Tr...

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta

Standard

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. / Sandmann, Lisa; Yurdaydin, Cihan; Deterding, Katja; Heidrich, Benjamin; Hardtke, Svenja; Lehmann, Patrick; Bremer, Birgit; Manns, Michael P; Cornberg, Markus; Wedemeyer, Heiner; Maasoumy, Benjamin; HIDIT-II Study Group.

in: HEPATOL COMMUN, Jahrgang 6, Nr. 3, 03.2022, S. 480-495.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Sandmann, L, Yurdaydin, C, Deterding, K, Heidrich, B, Hardtke, S, Lehmann, P, Bremer, B, Manns, MP, Cornberg, M, Wedemeyer, H, Maasoumy, B & HIDIT-II Study Group 2022, 'HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta', HEPATOL COMMUN, Jg. 6, Nr. 3, S. 480-495. https://doi.org/10.1002/hep4.1821

APA

Sandmann, L., Yurdaydin, C., Deterding, K., Heidrich, B., Hardtke, S., Lehmann, P., Bremer, B., Manns, M. P., Cornberg, M., Wedemeyer, H., Maasoumy, B., & HIDIT-II Study Group (2022). HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. HEPATOL COMMUN, 6(3), 480-495. https://doi.org/10.1002/hep4.1821

Vancouver

Sandmann L, Yurdaydin C, Deterding K, Heidrich B, Hardtke S, Lehmann P et al. HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. HEPATOL COMMUN. 2022 Mär;6(3):480-495. https://doi.org/10.1002/hep4.1821

Bibtex

@article{dac53be506974307b29b0760047745e3,
title = "HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta",
abstract = "Standard treatment of hepatitis delta virus (HDV) infection remains pegylated-interferon alfa (peg-IFNα) in most centers, which is not only associated with rather low efficacy but several adverse events. Hepatitis B core-related antigen (HBcrAg) is linked to intrahepatic covalently closed circular DNA levels and has previously been suggested as response predictor in IFN-based treatment of hepatitis B virus (HBV) mono-infection. This study aimed to investigate the value of HBcrAg in the management of patients with HBV/HDV co-infection undergoing peg-IFNα treatment. The Hep-Net-International-Delta-Hepatitis-Intervention Trial-2 study included 120 patients co-infected with HBV/HDV. Patients were treated for 96 weeks with peg-IFNα and either tenofovir or placebo. Ninety-nine patients with HDV-RNA results 24 weeks after end of treatment (FU24) were included in this analysis, of whom 32 patients (32.3%) had undetectable HDV RNA at FU24. HBcrAg was measured at baseline, week 12, 24, 48, 96, and FU24. HBcrAg levels showed no significant correlation with HDV RNA but were significantly linked to treatment outcome. HBcrAg levels < 4.5 log IU/mL at baseline, week 24, and week 48 had high negative predictive value (NPV) for achieving undetectable HDV RNA at FU24 (81.8%, 87.1% and 95.0%, respectively). Similarly, HBcrAg levels at week 96 were significantly higher in patients with viral relapse until FU24 (3.0 vs. 3.63 log IU/mL; P = 0.0089). Baseline, week 24, and week 48 HBcrAg levels were also associated with the likelihood of achieving HBsAg level < 100 IU/mL at FU24 (HBcrAg < 3.0 log IU/mL: NPV 91.7%, 90.4% and 92.3%, respectively). Test statistics improved when combining HBcrAg with additional viral and clinical parameters. Conclusion: HBcrAg is linked to treatment response to peg-IFNα in patients with HBV/HDV co-infection and could be a promising marker to determine treatment futility.",
author = "Lisa Sandmann and Cihan Yurdaydin and Katja Deterding and Benjamin Heidrich and Svenja Hardtke and Patrick Lehmann and Birgit Bremer and Manns, {Michael P} and Markus Cornberg and Heiner Wedemeyer and Benjamin Maasoumy and {HIDIT-II Study Group}",
note = "{\textcopyright} 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.",
year = "2022",
month = mar,
doi = "10.1002/hep4.1821",
language = "English",
volume = "6",
pages = "480--495",
journal = "HEPATOL COMMUN",
issn = "2471-254X",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "3",

}

RIS

TY - JOUR

T1 - HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta

AU - Sandmann, Lisa

AU - Yurdaydin, Cihan

AU - Deterding, Katja

AU - Heidrich, Benjamin

AU - Hardtke, Svenja

AU - Lehmann, Patrick

AU - Bremer, Birgit

AU - Manns, Michael P

AU - Cornberg, Markus

AU - Wedemeyer, Heiner

AU - Maasoumy, Benjamin

AU - HIDIT-II Study Group

N1 - © 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

PY - 2022/3

Y1 - 2022/3

N2 - Standard treatment of hepatitis delta virus (HDV) infection remains pegylated-interferon alfa (peg-IFNα) in most centers, which is not only associated with rather low efficacy but several adverse events. Hepatitis B core-related antigen (HBcrAg) is linked to intrahepatic covalently closed circular DNA levels and has previously been suggested as response predictor in IFN-based treatment of hepatitis B virus (HBV) mono-infection. This study aimed to investigate the value of HBcrAg in the management of patients with HBV/HDV co-infection undergoing peg-IFNα treatment. The Hep-Net-International-Delta-Hepatitis-Intervention Trial-2 study included 120 patients co-infected with HBV/HDV. Patients were treated for 96 weeks with peg-IFNα and either tenofovir or placebo. Ninety-nine patients with HDV-RNA results 24 weeks after end of treatment (FU24) were included in this analysis, of whom 32 patients (32.3%) had undetectable HDV RNA at FU24. HBcrAg was measured at baseline, week 12, 24, 48, 96, and FU24. HBcrAg levels showed no significant correlation with HDV RNA but were significantly linked to treatment outcome. HBcrAg levels < 4.5 log IU/mL at baseline, week 24, and week 48 had high negative predictive value (NPV) for achieving undetectable HDV RNA at FU24 (81.8%, 87.1% and 95.0%, respectively). Similarly, HBcrAg levels at week 96 were significantly higher in patients with viral relapse until FU24 (3.0 vs. 3.63 log IU/mL; P = 0.0089). Baseline, week 24, and week 48 HBcrAg levels were also associated with the likelihood of achieving HBsAg level < 100 IU/mL at FU24 (HBcrAg < 3.0 log IU/mL: NPV 91.7%, 90.4% and 92.3%, respectively). Test statistics improved when combining HBcrAg with additional viral and clinical parameters. Conclusion: HBcrAg is linked to treatment response to peg-IFNα in patients with HBV/HDV co-infection and could be a promising marker to determine treatment futility.

AB - Standard treatment of hepatitis delta virus (HDV) infection remains pegylated-interferon alfa (peg-IFNα) in most centers, which is not only associated with rather low efficacy but several adverse events. Hepatitis B core-related antigen (HBcrAg) is linked to intrahepatic covalently closed circular DNA levels and has previously been suggested as response predictor in IFN-based treatment of hepatitis B virus (HBV) mono-infection. This study aimed to investigate the value of HBcrAg in the management of patients with HBV/HDV co-infection undergoing peg-IFNα treatment. The Hep-Net-International-Delta-Hepatitis-Intervention Trial-2 study included 120 patients co-infected with HBV/HDV. Patients were treated for 96 weeks with peg-IFNα and either tenofovir or placebo. Ninety-nine patients with HDV-RNA results 24 weeks after end of treatment (FU24) were included in this analysis, of whom 32 patients (32.3%) had undetectable HDV RNA at FU24. HBcrAg was measured at baseline, week 12, 24, 48, 96, and FU24. HBcrAg levels showed no significant correlation with HDV RNA but were significantly linked to treatment outcome. HBcrAg levels < 4.5 log IU/mL at baseline, week 24, and week 48 had high negative predictive value (NPV) for achieving undetectable HDV RNA at FU24 (81.8%, 87.1% and 95.0%, respectively). Similarly, HBcrAg levels at week 96 were significantly higher in patients with viral relapse until FU24 (3.0 vs. 3.63 log IU/mL; P = 0.0089). Baseline, week 24, and week 48 HBcrAg levels were also associated with the likelihood of achieving HBsAg level < 100 IU/mL at FU24 (HBcrAg < 3.0 log IU/mL: NPV 91.7%, 90.4% and 92.3%, respectively). Test statistics improved when combining HBcrAg with additional viral and clinical parameters. Conclusion: HBcrAg is linked to treatment response to peg-IFNα in patients with HBV/HDV co-infection and could be a promising marker to determine treatment futility.

U2 - 10.1002/hep4.1821

DO - 10.1002/hep4.1821

M3 - SCORING: Journal article

C2 - 34561972

VL - 6

SP - 480

EP - 495

JO - HEPATOL COMMUN

JF - HEPATOL COMMUN

SN - 2471-254X

IS - 3

ER -